Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vargatef

- PMLiVE

CDF chair regrets undermining NICE

But Prof Clark says he wholeheartedly supports the Institute

- PMLiVE

Boehringer drug approved in EU for rare lung disease

Nintedanib is already available as cancer treatment

- PMLiVE

EU approval for Lilly’s Cyramza in stomach cancer

Follows shortly after the drug's US approval in non-small cell lung cancer

EU flag

Boehringer’s Vargatef approved in the EU for lung cancer

Marks company’s second oncology drug to hit market

- PMLiVE

Integrating digital: developing a social conference

Boehringer Ingelheim’s director of oncology Albert van Eijk on the digital elements of its multichannel efforts

- PMLiVE

NICE backs Boehringer’s blood clot treatment Pradaxa

Draft DVT and PE guidance puts it on course to catch up with Bayer's Xarelto

- PMLiVE

Boehringer’s Ofev approved by FDA for rare lung disease

US regulator also gives the green light to Intermune's Esbriet

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Boehringer Ingelheim launches Sound Challenge app

Looks to raise awareness of rare lung disease IPF

- PMLiVE

Almost half of cancer patients diagnosed ‘too late’

Cancer Research UK claims 46% are diagnosed at advanced stage

- PMLiVE

Bruce Peacock joins Dicerna from Ophthotech

He is appointed to its board of directors and audit committee

- PMLiVE

Major depression in UK cancer patients going untreated

Only 17% of patients reacted to usual NHS therapy according to new research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links